Aberdeen Group plc Raises Stock Holdings in Quanterix Corporation $QTRX

Aberdeen Group plc boosted its stake in shares of Quanterix Corporation (NASDAQ:QTRX) by 34.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 564,581 shares of the company’s stock after buying an additional 143,725 shares during the quarter. Aberdeen Group plc owned approximately 1.21% of Quanterix worth $3,066,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in QTRX. HUB Investment Partners LLC purchased a new position in shares of Quanterix in the second quarter valued at $81,000. Brevan Howard Capital Management LP purchased a new position in shares of Quanterix in the second quarter valued at about $96,000. State of Wyoming lifted its holdings in Quanterix by 105.3% in the 2nd quarter. State of Wyoming now owns 14,814 shares of the company’s stock worth $99,000 after buying an additional 7,599 shares during the period. Vanguard Personalized Indexing Management LLC raised its holdings in Quanterix by 40.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,024 shares of the company’s stock worth $100,000 after purchasing an additional 4,330 shares in the last quarter. Finally, Quantbot Technologies LP lifted its holdings in Quanterix by 182.7% in the second quarter. Quantbot Technologies LP now owns 31,864 shares of the company’s stock worth $212,000 after buying an additional 20,592 shares during the period. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Quanterix Stock Down 3.2%

Quanterix stock opened at $5.76 on Friday. The company has a market cap of $269.05 million, a PE ratio of -2.47 and a beta of 1.09. The company’s 50-day moving average price is $6.60 and its 200-day moving average price is $5.94. Quanterix Corporation has a twelve month low of $4.05 and a twelve month high of $8.77.

Analyst Ratings Changes

A number of brokerages recently issued reports on QTRX. Wall Street Zen raised shares of Quanterix from a “sell” rating to a “hold” rating in a research report on Monday, December 29th. Canaccord Genuity Group lifted their target price on shares of Quanterix from $5.00 to $8.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Quanterix in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $11.33.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.